ImmunityBio converts from Immunomedics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunityBio converts from Immunomedics

IBRX 2.139

+0.9%

Nov 7 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

bobbseytwins2001

JJINV

To: Redman1234 who wrote (831)	1/16/2025 2:26:10 PM
From: Redman1234	2 Recommendations of 1232

Another humdinger of a post from huggenberg. All I can say is wow! $IBRX Revenue in NSCLC following the ResQ-201 protocol: Induction Phase: six weekly applications Maintenance Phase: three weekly applications = 9 x $35.800 x 730’000 = 235’206'000’000$ 5% market penetration is possible, and this would be 12B$ alone in NSCLC

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next